- Home >
- Clinicals Trials >
- ROCSAN
Back to clinical trials listCancers gynécologiques
ROCSAN
A multicentric randomized phase II/III evaluating TSR-042 (anti-PD-1 mAb) in combination with Niraparib (parpi) versus Niraparib alone compared to chemotherapy in the treatment of metastatic or recurrent endometrial or ovarian carcinosarcoma after at least one line of chemotherapy
- Open at Paris since : 28/05/2025
- Target : Adult
- Phase : Phase II/III
Trial description
Niraparib is an orally available, potent, highly selective poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) -1 and -2 inhibitor.;TSR-042 (Dostarlimab) is a humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1; programmed death-1), with potential immune checkpoint inhibitory and antineoplastic activities.;The chemotherapy consists of Paclitaxel/PLD/Topotecan for patients with ovarian cancer and Doxorubicin/Paclitaxel/Gemcitabine for patients with endometrial cancer.
Main investigator
